Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2000

01-03-2000

Analysis of cathepsin D in human breast cancer: Usefulness of the processsed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients

Authors: Lee B. Riley, Marianne K. Lange, Richard J. Browne, Peter J. Cochrane, Ik-Joon Choi, Barbara Davis, Stephen Arcona, Jack A. Alhadeff

Published in: Breast Cancer Research and Treatment | Issue 2/2000

Login to get access
Metadata
Title
Analysis of cathepsin D in human breast cancer: Usefulness of the processsed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients
Authors
Lee B. Riley
Marianne K. Lange
Richard J. Browne
Peter J. Cochrane
Ik-Joon Choi
Barbara Davis
Stephen Arcona
Jack A. Alhadeff
Publication date
01-03-2000
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2000
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006394401199

Other articles of this Issue 2/2000

Breast Cancer Research and Treatment 2/2000 Go to the issue

OriginalPaper

EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer

OriginalPaper

RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters

OriginalPaper

Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers

OriginalPaper

Microsatellite instability markers in breast cancer: A review and study showing MSI was not detected at ‘BAT 25’ and ‘BAT 26’ microsatellite markers in early-onset breast cancer

OriginalPaper

Eye problems in breast cancer patients treated with tamoxifen

OriginalPaper

Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits